Search Result

Results for "

Novel antibiotics

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (12) Bacterial (11) Reference Standards (1) Topoisomerase (2)
By Research Areas:	Cancer (2) Infection (16) Inflammation/Immunology (2)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Antibiotic

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139628

JPD447	Bacterial	Infection Cancer
JPD447, a MAC-0547630 derivative, is a novel class of UppS inhibitor to potentiate β-lactam antibiotics.

HY-100180

Delpazolid 1 Publications Verification LCB01-0371	Bacterial Antibiotic	Infection
Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC₉₀ of 2 μg/mL for both of them.

HY-125732

Decarestrictine D	Antibiotic	Infection
Decarestrictine D exhibits inhibitory activity against cholesterol levels. Decarestrictine D is utilized as receptor for glycosylation reactions to synthesize novel hybrid antibiotics .

HY-12450

Lomofungin Lomondomycin	Antibiotic Bacterial	Infection
Lomofungin is a novel antibiotic produced by Streptomyces lomondensis sp.N . Lomofungin can inhibit MBNL1-CUG RNA binding. Lomofungin has antibacterial activity .

HY-P1974

FR 901379 WF11899A	Antibiotic	Infection
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

HY-118132

LL-Z1220	Antibiotic	Infection
LL-Z1220 is a novel antibiotic with the structure of 2-(3,8-dioxopentacyclo[5.1.0.0^~^~]oct-5-en-5-yl)-4H-pyran-4-one. This appears to be the first reported natural product containing a benzene dioxide group. This antibiotic readily undergoes valence isomerization to form 1,4-dioxopentacyclo. The chemical and spectroscopic properties of the antibiotic suggest that the benzene dioxide has a cis configuration.

HY-170609

Antimicrobial agent-36	Bacterial	Infection
Antimicrobial agent-36 (Compound 8b) is an antimicrobial agent that significantly inhibits the level of DNA gyrase, with an IC₅₀ value of 4.56 µM. Antimicrobial agent-36 can also be used for the preparation of nanopharmaceutical formulations, for the research and development of novel antibiotics .

HY-178952

Anti-infective agent 12	Bacterial	Infection
Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC₅₀ of 4.475 μM and a K_d of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models. Anti-infective agent 12 reduces the risk of drug resistance caused by single-target mutations. Anti-infective agent 12 can be used to study infections caused by multi-drug resistant Gram-positive bacteria .

HY-111333

Pyrroxamycin Dioxapyrrolomycin; LL-F42248α; AL-R2081	Bacterial	Infection
Pyrroxamycin is a novel antibiotic produced by Streptomyces, whose chemical structure was determined by chemical properties and X-ray crystallography and 13C NMR spectroscopy analysis. It is active against Gram-positive bacteria and dermatophytes. In this paper, the authors discuss the taxonomy, fermentation, isolation, physicochemical properties, chemical structure, and biological activity of the strain producing Pyrroxamycin.

HY-121716

Pelagiomicin A Antibiotic 2088A; LL-14I352α	Bacterial	Cancer
Pelagiomicin A is a novel phenazine antibiotic produced by the marine bacterium Pelagiobacter variabilis. The compound is unstable in water and small alcohols. The absolute structure of its major component, Pelagiomicin A, as well as the properties of minor amounts of other structures, were determined by spectroscopic data and synthesis. Pelagiomicin A is active against both Gram-positive and Gram-negative bacteria and exhibits antitumor activity in vitro and in vivo.

HY-106410A

Zabofloxacin hydrochloride DW-224a	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin hydrochloride (DW-224a) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin hydrochloride has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia. Zabofloxacin hydrochloride is a novel fluoronaphthyridone quinolone that is considered as an alternative *antibiotic* for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-106410

Zabofloxacin DW-224a Free base	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-A0062

Telithromycin 5 Publications Verification HMR3647; RU66647	Bacterial Antibiotic	Infection Inflammation/Immunology
Telithromycin (HMR3647) is a novel ketolide antibiotic that structurally resembles macrolides. Telithromycin belongs to the ketolide family that is characterized by a keto group at position 3 of the macrolide ring and is active against bacteria causing community-acquired pneumonia, acute exacerbation of chronic bronchitis, and acute sinusitis. Telithromycin also has similar immunomodulatory effects as macrolides. Telithromycin can be used for the research of respiratory infections including bronchial asthma .

HY-123429

CK0683A	Antibiotic	Infection
CK0683A is a novel biaminourea antibiotic with antiplaque effects and demonstrated efficacy in experimental mouse dental disease models. A 12-week study in beagles compared its efficacy in terms of plaque and gingivitis reduction, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease is similar to that of humans. As a positive control for plaque and gingivitis reduction and staining, chlorhexidine acetate was selected because it is effective in both humans and dogs.

HY-121120

Isosulfazecin	Antibiotic	Infection
Isosulfazecin (iSZ) is a novel β-lactam antibiotic produced by Pseudomonas acidophilus sp., synthesized in a nutrient solution supplemented with glycerol and sodium thiosulfate under aerobic conditions in parallel with bacterial growth. It is purified by chromatography and crystallization from aqueous methanol. Physicochemical analysis determined its molecular formula to be C12H20N4O9S, showing a structure with a β-lactam ring, methoxyl and sulfonate groups. Acid hydrolysis yields L-alanine and D-glutamic acid. iSZ is a diastereomer of sulfadiazine and exhibits moderate activity against both gram-positive and gram-negative bacteria, but potent activity against bacteria resistant to β-lactam antibiotics .

HY-123479

CK0492B	Antibiotic	Infection
CK0492B is a novel biaminourea antibiotic that has antiplaque properties in vitro and has shown efficacy in an experimental mouse dental disease model. A 12-week study in beagles compared its efficacy in reducing plaque and gingivitis, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease are similar to humans. Chlorhexidine acetate was selected as a positive control for plaque and gingivitis reduction and staining because it is effective in both humans and dogs.

HY-A0062R

Telithromycin (Standard) HMR3647 (Standard); RU66647 (Standard)	Reference Standards Bacterial Antibiotic	Infection Inflammation/Immunology
Telithromycin (Standard) is the analytical standard of Telithromycin. This product is intended for research and analytical applications. Telithromycin (HMR3647) is a novel ketolide antibiotic that structurally resembles macrolides. Telithromycin belongs to the ketolide family that is characterized by a keto group at position 3 of the macrolide ring and is active against bacteria causing community-acquired pneumonia, acute exacerbation of chronic bronchitis, and acute sinusitis. Telithromycin also has similar immunomodulatory effects as macrolides. Telithromycin can be used for the research of respiratory infections including bronchial asthma .

Cat. No.	Product Name	Target	Research Area

HY-P1974

FR 901379 WF11899A	Antibiotic	Infection
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-125732

Decarestrictine D	Human Gut Microbiota Metabolites Microorganisms Macrolide Antibiotics Antibiotics Source classification Endogenous metabolite	Antibiotic
Decarestrictine D exhibits inhibitory activity against cholesterol levels. Decarestrictine D is utilized as receptor for glycosylation reactions to synthesize novel hybrid antibiotics .

HY-12450

Lomofungin Lomondomycin	Microorganisms Antibiotics Source classification	Antibiotic Bacterial
Lomofungin is a novel antibiotic produced by Streptomyces lomondensis sp.N . Lomofungin can inhibit MBNL1-CUG RNA binding. Lomofungin has antibacterial activity .

HY-P1974

FR 901379 WF11899A	Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

HY-111333

Pyrroxamycin Dioxapyrrolomycin; LL-F42248α; AL-R2081	Microorganisms Antibiotics Source classification	Bacterial
Pyrroxamycin is a novel antibiotic produced by Streptomyces, whose chemical structure was determined by chemical properties and X-ray crystallography and 13C NMR spectroscopy analysis. It is active against Gram-positive bacteria and dermatophytes. In this paper, the authors discuss the taxonomy, fermentation, isolation, physicochemical properties, chemical structure, and biological activity of the strain producing Pyrroxamycin.

HY-121716

Pelagiomicin A Antibiotic 2088A; LL-14I352α	Antibiotics Marine natural products Source classification	Bacterial
Pelagiomicin A is a novel phenazine antibiotic produced by the marine bacterium Pelagiobacter variabilis. The compound is unstable in water and small alcohols. The absolute structure of its major component, Pelagiomicin A, as well as the properties of minor amounts of other structures, were determined by spectroscopic data and synthesis. Pelagiomicin A is active against both Gram-positive and Gram-negative bacteria and exhibits antitumor activity in vitro and in vivo.

HY-121120

Isosulfazecin	Microorganisms Antibiotics Source classification Beta-lactam Antibiotics	Antibiotic
Isosulfazecin (iSZ) is a novel β-lactam antibiotic produced by Pseudomonas acidophilus sp., synthesized in a nutrient solution supplemented with glycerol and sodium thiosulfate under aerobic conditions in parallel with bacterial growth. It is purified by chromatography and crystallization from aqueous methanol. Physicochemical analysis determined its molecular formula to be C12H20N4O9S, showing a structure with a β-lactam ring, methoxyl and sulfonate groups. Acid hydrolysis yields L-alanine and D-glutamic acid. iSZ is a diastereomer of sulfadiazine and exhibits moderate activity against both gram-positive and gram-negative bacteria, but potent activity against bacteria resistant to β-lactam antibiotics .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Novel antibiotics

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products